Identification of α2β1 integrin inhibitor VP-i with anti-platelet properties in the venom of Vipera palaestinae

Toxicon

Volumn 64, Issue , 2013, Pages 96-105

  Arlinghaus, Franziska T ^a   Momic, Tatjana ^b   Ammar, Narmeen Abu ^b,c   Shai, Ela ^c   Spectre, Galia ^c   Varon, David ^c   Marcinkiewicz, Cezary ^d   Heide, Heinrich ^a   Lazarovici, Philip ^b   Eble, Johannes A ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d TEMPLE UNIVERSITY   (United States)

Author keywords

A domain; C type lectin related protein; Integrin 2 1; VP12

Indexed keywords

COLLAGEN TYPE 1; SNAKE VENOM; VERY LATE ACTIVATION ANTIGEN 2;

AFFINITY CHROMATOGRAPHY; ARTICLE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; THROMBOCYTE AGGREGATION INHIBITION; VIPERA; VIPERA PALESTINAE;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; FIBROSARCOMA; HUMANS; INTEGRIN ALPHA2BETA1; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; VIPER VENOMS; VIPERIDAE;

EID: 84873607002     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2013.01.001     Document Type: Article

References (28)

1. Arlinghaus F.T., Eble J.A. C-type lectin-like proteins from snake venoms. Toxicon 2012, 60:512-519.
2. Arlinghaus F.T., Eble J.A. The collagen-binding integrin alpha2beta1 is a novel interaction partner of the T. flavoviridis venom protein flavocetin-A. Journal of Biological Chemistry 2013, 288(2):947-955.
3. Barczyk M., Carracedo S., Gullberg D. Integrins. Cell. Tissue Res. 2010, 339:269-280.
4. Bazan-Socha S., Kisiel D.G., Young B., Theakston R.D., Calvete J.J., Sheppard D., Marcinkiewicz C. Structural requirements of MLD-containing disintegrins for functional interaction with alpha 4 beta 1 and alpha 9 beta1 integrins. Biochemistry 2004, 43:1639-1647.
5. Born G.V., Cross M.J. Effect of adenosine diphosphate on the concentration of platelets in circulating blood. Nature 1963, 197:974-976.
6. Broos K., De Meyer S.F., Feys H.B., Vanhoorelbeke K., Deckmyn H. Blood platelet biochemistry. Thromb. Res. 2012, 129:245-249.
7. Clemetson K.J., Clemetson J.M. Platelet GPIb complex as a target for anti-thrombotic drug development. Thromb. Haemost 2008, 99:473-479.
8. Clemetson K.J. Snaclecs (snake C-type lectins) that inhibit or activate platelets by binding to receptors. Toxicon 2010, 56:1236-1246.
9. de Rezende F.F., Martins Lima A., Niland S., Wittig I., Heide H., Schroder K., Eble J.A. Integrin alpha7beta1 is a redox-regulated target of hydrogen peroxide in vascular smooth muscle cell adhesion. Free Radic. Biol. Med. 2012, 53:521-531.
10. Eble J.A., Tuckwell D.S. The alpha2beta1 integrin inhibitor rhodocetin binds to the A-domain of the integrin alpha2 subunit proximal to the collagen-binding site. Biochem. J. 2003, 376:77-85.
11. Eble J.A., Niland S., Dennes A., Schmidt-Hederich A., Bruckner P., Brunner G. Rhodocetin antagonizes stromal tumor invasion in vitro and other alpha2beta1 integrin-mediated cell functions. Matrix Biol. 2002, 21:547-558.
12. Eble J.A., Niland S., Bracht T., Mormann M., Peter-Katalinic J., Pohlentz G., Stetefeld J. The alpha2beta1 integrin-specific antagonist rhodocetin is a cruciform, heterotetrameric molecule. Faseb. J. 2009, 23:2917-2927.
13. Eble J.A. Collagen-binding integrins as pharmaceutical targets. Curr. Pharm. Des. 2005, 11:867-880.
14. Eckes B., Zweers M.C., Zhang Z.G., Hallinger R., Mauch C., Aumailley M., Krieg T. Mechanical tension and integrin alpha 2 beta 1 regulate fibroblast functions. J. Investig. Dermatol. Symp. Proc. 2006, 11:66-72.
15. Emsley J., Knight C.G., Farndale R.W., Barnes M.J., Liddington R.C. Structural basis of collagen recognition by integrin alpha2beta1. Cell 2000, 101:47-56.
16. Heino J. The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol. 2000, 19:319-323.
17. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69:11-25.
18. Marcinkiewicz C., Lobb R.R., Marcinkiewicz M.M., Daniel J.L., Smith J.B., Dangelmaier C., Weinreb P.H., Beacham D.A., Niewiarowski S. Isolation and characterization of EMS16, a C-lectin type protein from Echis multisquamatus venom, a potent and selective inhibitor of the alpha2beta1 integrin. Biochemistry 2000, 39:9859-9867.
19. Momic T., Arlinghaus F.T., Arien-Zakay H., Katzhendler J., Eble J.A., Marcinkiewicz C., Lazarovici P. Pharmacological aspects of vipera xantina palestinae venom. Toxins (Basel) 2011, 3:1420-1432.
20. Morita T. Structure-function relationships of C-type lectin-related proteins. Pathophysiol. Haemost. Thromb. 2005, 34:156-159.
21. Nuyttens B.P., Thijs T., Deckmyn H., Broos K. Platelet adhesion to collagen. Thromb. Res. 2011, 127(Suppl. 2):S26-S29.
22. Ogawa T., Chijiwa T., Oda-Ueda N., Ohno M. Molecular diversity and accelerated evolution of C-type lectin-like proteins from snake venom. Toxicon 2005, 45:1-14.
23. Pilorget A., Conesa M., Sarray S., Michaud-Levesque J., Daoud S., Kim K.S., Demeule M., Marvaldi J., El Ayeb M., Marrakchi N., Beliveau R., Luis J. Lebectin, a Macrovipera lebetina venom-derived C-type lectin, inhibits angiogenesis both in vitro and in vivo. J. Cell. Physiol. 2007, 211:307-315.
24. Shaw L.M. Integrin function in breast carcinoma progression. J. Mammary Gland Biol. Neoplasia 1999, 4:367-376.
25. Staniszewska I., Walsh E.M., Rothman V.L., Gaathon A., Tuszynski G.P., Calvete J.J., Lazarovici P., Marcinkiewicz C. Effect of VP12 and viperistatin on inhibition of collagen-receptor-dependent melanoma metastasis. Cancer Biol. Ther. 2009, 8:1507-1516.
26. Takada Y., Ye X., Simon S. The integrins. Genome Biol. 2007, 8:215.
27. Wong E.S., Belov K. Venom evolution through gene duplications. Gene 2012, 496:1-7.
28. Zutter M.M., Sun H., Santoro S.A. Altered integrin expression and the malignant phenotype: the contribution of multiple integrated integrin receptors. J. Mammary Gland Biol. Neoplasia 1998, 3:191-200.